Juniper Pharmaceuticals (JNP) Stock Price, News & Analysis

Company Overview

Juniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. It operates in two segments, Product and Service. The company develops its products utilizing its proprietary drug delivery technologies, which include bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa to achieve sustained and controlled delivery of active drug product; and a novel intravaginal ring technology. Juniper Pharmaceuticals, Inc. markets Crinone, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. Its product candidates include JNP-0101, which is designed to deliver oxybutynin for the treatment of overactive bladder in women; JNP-0201, which contains natural progesterone and estradiol to be used for hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone for the prevention of preterm birth in women with a short cervical length. The company offers pharmaceutical product development; clinical trial manufacturing; and analytical and consulting services. Juniper Pharmaceuticals, Inc. has collaboration agreements with Merck KGaA and Allergan, as well as patent license agreement with Massachusetts General Hospital. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $11.45 to $11.50
• 50-Day Range: N/A
• 52-Week Range: $4.30 to $13.25
• Volume: 28,513 shs
• Average Volume: 155,873 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

JNP Stock Analysis - Frequently Asked Questions

How were Juniper Pharmaceuticals' earnings last quarter?

Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) posted its earnings results on Thursday, August, 9th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of $0.04 by $0.18. The specialty pharmaceutical company had revenue of $15.31 million for the quarter, compared to analysts' expectations of $16.30 million.

What other stocks do shareholders of Juniper Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Juniper Pharmaceuticals investors own include Novavax (NVAX), Bristol Myers Squibb (BMY), Verastem (VSTM), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Rigel Pharmaceuticals (RIGL) and Synergy Pharmaceuticals (SGYP).

Company Calendar

• Last Earnings: 8/09/2018
• Today: 8/04/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:JNP
• CIK: 821995
• Web: www.juniperpharma.com
• Phone: 617-639-1500
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A